Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Artiva Biotherapeutics, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Why Is Artiva Biotherapeutics, Inc. (ARTV) Under Investigation?
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of shareholders of Artiva Biotherapeutics, Inc. (NASDAQ: ARTV).
On October 27, 2026, Artiva announced that it is discontinuing further development of AlloNK® (AB-101), its lead allogeneic natural killer (NK) cell therapy candidate being evaluated for rheumatoid arthritis and other B-cell-driven autoimmune diseases. Artiva disclosed that the decision followed a review of updated longer-term clinical data, which revealed that the durability of clinical responses did not meet expectations, alongside recent Grade 5 (fatal) safety events involving the deaths of two patients in its clinical studies. In connection with halting its lead program, Artiva announced it is implementing a massive workforce reduction of approximately 94% and exploring strategic alternatives that may include a merger, asset sale, or complete dissolution and liquidation. Following this news, Artiva’s stock price fell $1.89 per share, or 30.68%, to close at $4.27 per share on October 27, 2026.
What Potential Securities Violations Is BG&G Investigating?
- Whether Artiva Biotherapeutics, Inc. and certain of its officers made false or misleading statements regarding the Company's financial condition and business prospects.
- Whether Artiva Biotherapeutics, Inc. failed to disclose material adverse information that would have been significant to a reasonable investor.
- Whether the Company's earnings guidance was supported by a reasonable factual basis at the time it was made.
What Should Artiva Biotherapeutics, Inc. (ARTV) Investors Do?
How Is Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) Stock Trading Today?
How Does BG&G Help Investors in Securities Fraud Investigations?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
We handle cases on a contingency fee basis — we advance all litigation costs on your behalf. There is no fee unless we are successful.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”